Novel GLP-1/anti-apolipoprotein B bifunctional fusion protein alleviates diabetes and diabetic complications in combination with low-intensity ultrasound
To engineer and screen a novel GLP-1/anti-apolipoprotein B (apoB) bifunctional fusion protein with therapeutic potential on alleviating diabetes and diabetic complication in combination with low-intensity ultrasound. Anti-apoB antibodies were screened by phage display technology and further fused to...
Gespeichert in:
| Veröffentlicht in: | Life sciences (1973) 2021-08, Vol.278, p.119549-119549, Article 119549 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119549 |
|---|---|
| container_issue | |
| container_start_page | 119549 |
| container_title | Life sciences (1973) |
| container_volume | 278 |
| creator | Li, Xing Bai, Lianjie Zhang, Yinghui Wang, Ying Shi, Yang Liu, Huilin |
| description | To engineer and screen a novel GLP-1/anti-apolipoprotein B (apoB) bifunctional fusion protein with therapeutic potential on alleviating diabetes and diabetic complication in combination with low-intensity ultrasound.
Anti-apoB antibodies were screened by phage display technology and further fused to mutated GLP-1 (7–37) via light or heavy fusion to generate bifunctional fusion protein (termed aBG). The optimal design of aBG fusion protein was further confirmed by in vitro epitope competition assay and cAMP accumulation assay. Subsequently, chronic study in DIO mice were subjected to assess the long-term efficacy of screened fusion protein.
The selected GLP-1/anti-apoB fusion protein, aBG-8, exerted either the highest binding affinities for GLP-1R and apoB, or the greatest LDL-C uptake capacity and GLP-1R activation activity. After 60-day treatment in DIO mice, aBG-8 was proved to exert the promising improvement on hyperglycemia, hyperlipidemia, and obesity in DIO mice. Furthermore, combined therapy of aBG-8 and low-intensity ultrasound could accelerate skin wound closure in diabetic mice.
A novel long-lasting bifunctional fusion molecule, aBG-8, was designed with the enormous potential on alleviating diabetes and diabetic complications in combination with low-intensity ultrasound. |
| doi_str_mv | 10.1016/j.lfs.2021.119549 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2521497642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002432052100535X</els_id><sourcerecordid>2545254163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-ae17677ae11fcedde858c1d750d3b1e051d02667fedfba57204ca06bc7a7b9e23</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EokvhAbggS1y4ZGvHcbwRJ1pBQVq1HOBsOfZEzMprh9jZqo_St8Vhtxw49GDNH_--kWY-Qt5ytuaMtxe7tR_SumY1X3PeyaZ7RlZ8o7qKtYI_JyvG6qYSNZNn5FVKO8aYlEq8JGdCdEI0sluRh5t4AE-vt98rfmFCxsqM0eMYxylmwEAvaY_DHGzGGIynw5xKQh9_jfdwQJMhUYemhyUxwZ0KtNTG_ejRmkWeaFGURo_hb03vMP-iPt5VGDKEhPmezj5PJsU5uNfkxWB8gjeneE5-fvn84-prtb29_nb1aVtZseG5MsBVq1QJfLDgHGzkxnKnJHOi58Akd6xuWzWAG3ojVc0aa1jbW2VU30EtzsmH49yy0-8ZUtZ7TBa8NwHinHQta950qm0W9P1_6C7OUznLQjWyPN6KQvEjZaeY0gSDHifcm-lec6YX3_ROF9_04ps--lY0706T534P7p_i0agCfDwCUE5xQJh0sgihbIwT2KxdxCfG_wGDRqxC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2545254163</pqid></control><display><type>article</type><title>Novel GLP-1/anti-apolipoprotein B bifunctional fusion protein alleviates diabetes and diabetic complications in combination with low-intensity ultrasound</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Li, Xing ; Bai, Lianjie ; Zhang, Yinghui ; Wang, Ying ; Shi, Yang ; Liu, Huilin</creator><creatorcontrib>Li, Xing ; Bai, Lianjie ; Zhang, Yinghui ; Wang, Ying ; Shi, Yang ; Liu, Huilin</creatorcontrib><description>To engineer and screen a novel GLP-1/anti-apolipoprotein B (apoB) bifunctional fusion protein with therapeutic potential on alleviating diabetes and diabetic complication in combination with low-intensity ultrasound.
Anti-apoB antibodies were screened by phage display technology and further fused to mutated GLP-1 (7–37) via light or heavy fusion to generate bifunctional fusion protein (termed aBG). The optimal design of aBG fusion protein was further confirmed by in vitro epitope competition assay and cAMP accumulation assay. Subsequently, chronic study in DIO mice were subjected to assess the long-term efficacy of screened fusion protein.
The selected GLP-1/anti-apoB fusion protein, aBG-8, exerted either the highest binding affinities for GLP-1R and apoB, or the greatest LDL-C uptake capacity and GLP-1R activation activity. After 60-day treatment in DIO mice, aBG-8 was proved to exert the promising improvement on hyperglycemia, hyperlipidemia, and obesity in DIO mice. Furthermore, combined therapy of aBG-8 and low-intensity ultrasound could accelerate skin wound closure in diabetic mice.
A novel long-lasting bifunctional fusion molecule, aBG-8, was designed with the enormous potential on alleviating diabetes and diabetic complications in combination with low-intensity ultrasound.</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2021.119549</identifier><identifier>PMID: 33933459</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Animals ; Antibodies ; Antibodies - therapeutic use ; apoB ; Apolipoprotein B ; Apolipoproteins ; Apolipoproteins B - antagonists & inhibitors ; CHO Cells ; Complications ; Cricetulus ; Diabetes ; Diabetes Complications - pathology ; Diabetes Complications - therapy ; Diabetes mellitus ; Diabetes Mellitus - pathology ; Diabetes Mellitus - therapy ; Diabetes Mellitus, Experimental - pathology ; Diabetes Mellitus, Experimental - therapy ; Diabetic complication ; Display devices ; Epitopes ; Fusion protein ; GLP-1 ; Glucagon-Like Peptide 1 - therapeutic use ; Hep G2 Cells ; Humans ; Hyperglycemia ; Hyperlipidemia ; Low density lipoprotein ; Low-intensity ultrasound ; Male ; Mice ; Mice, Inbred C57BL ; Phage display ; Phages ; Proteins ; Recombinant Fusion Proteins - therapeutic use ; Ultrasonic imaging ; Ultrasonic testing ; Ultrasonic Therapy - methods ; Ultrasound</subject><ispartof>Life sciences (1973), 2021-08, Vol.278, p.119549-119549, Article 119549</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier BV Aug 1, 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-ae17677ae11fcedde858c1d750d3b1e051d02667fedfba57204ca06bc7a7b9e23</citedby><cites>FETCH-LOGICAL-c381t-ae17677ae11fcedde858c1d750d3b1e051d02667fedfba57204ca06bc7a7b9e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S002432052100535X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33933459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Xing</creatorcontrib><creatorcontrib>Bai, Lianjie</creatorcontrib><creatorcontrib>Zhang, Yinghui</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Shi, Yang</creatorcontrib><creatorcontrib>Liu, Huilin</creatorcontrib><title>Novel GLP-1/anti-apolipoprotein B bifunctional fusion protein alleviates diabetes and diabetic complications in combination with low-intensity ultrasound</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>To engineer and screen a novel GLP-1/anti-apolipoprotein B (apoB) bifunctional fusion protein with therapeutic potential on alleviating diabetes and diabetic complication in combination with low-intensity ultrasound.
Anti-apoB antibodies were screened by phage display technology and further fused to mutated GLP-1 (7–37) via light or heavy fusion to generate bifunctional fusion protein (termed aBG). The optimal design of aBG fusion protein was further confirmed by in vitro epitope competition assay and cAMP accumulation assay. Subsequently, chronic study in DIO mice were subjected to assess the long-term efficacy of screened fusion protein.
The selected GLP-1/anti-apoB fusion protein, aBG-8, exerted either the highest binding affinities for GLP-1R and apoB, or the greatest LDL-C uptake capacity and GLP-1R activation activity. After 60-day treatment in DIO mice, aBG-8 was proved to exert the promising improvement on hyperglycemia, hyperlipidemia, and obesity in DIO mice. Furthermore, combined therapy of aBG-8 and low-intensity ultrasound could accelerate skin wound closure in diabetic mice.
A novel long-lasting bifunctional fusion molecule, aBG-8, was designed with the enormous potential on alleviating diabetes and diabetic complications in combination with low-intensity ultrasound.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies - therapeutic use</subject><subject>apoB</subject><subject>Apolipoprotein B</subject><subject>Apolipoproteins</subject><subject>Apolipoproteins B - antagonists & inhibitors</subject><subject>CHO Cells</subject><subject>Complications</subject><subject>Cricetulus</subject><subject>Diabetes</subject><subject>Diabetes Complications - pathology</subject><subject>Diabetes Complications - therapy</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - pathology</subject><subject>Diabetes Mellitus - therapy</subject><subject>Diabetes Mellitus, Experimental - pathology</subject><subject>Diabetes Mellitus, Experimental - therapy</subject><subject>Diabetic complication</subject><subject>Display devices</subject><subject>Epitopes</subject><subject>Fusion protein</subject><subject>GLP-1</subject><subject>Glucagon-Like Peptide 1 - therapeutic use</subject><subject>Hep G2 Cells</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hyperlipidemia</subject><subject>Low density lipoprotein</subject><subject>Low-intensity ultrasound</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Phage display</subject><subject>Phages</subject><subject>Proteins</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Ultrasonic imaging</subject><subject>Ultrasonic testing</subject><subject>Ultrasonic Therapy - methods</subject><subject>Ultrasound</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EokvhAbggS1y4ZGvHcbwRJ1pBQVq1HOBsOfZEzMprh9jZqo_St8Vhtxw49GDNH_--kWY-Qt5ytuaMtxe7tR_SumY1X3PeyaZ7RlZ8o7qKtYI_JyvG6qYSNZNn5FVKO8aYlEq8JGdCdEI0sluRh5t4AE-vt98rfmFCxsqM0eMYxylmwEAvaY_DHGzGGIynw5xKQh9_jfdwQJMhUYemhyUxwZ0KtNTG_ejRmkWeaFGURo_hb03vMP-iPt5VGDKEhPmezj5PJsU5uNfkxWB8gjeneE5-fvn84-prtb29_nb1aVtZseG5MsBVq1QJfLDgHGzkxnKnJHOi58Akd6xuWzWAG3ojVc0aa1jbW2VU30EtzsmH49yy0-8ZUtZ7TBa8NwHinHQta950qm0W9P1_6C7OUznLQjWyPN6KQvEjZaeY0gSDHifcm-lec6YX3_ROF9_04ps--lY0706T534P7p_i0agCfDwCUE5xQJh0sgihbIwT2KxdxCfG_wGDRqxC</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Li, Xing</creator><creator>Bai, Lianjie</creator><creator>Zhang, Yinghui</creator><creator>Wang, Ying</creator><creator>Shi, Yang</creator><creator>Liu, Huilin</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20210801</creationdate><title>Novel GLP-1/anti-apolipoprotein B bifunctional fusion protein alleviates diabetes and diabetic complications in combination with low-intensity ultrasound</title><author>Li, Xing ; Bai, Lianjie ; Zhang, Yinghui ; Wang, Ying ; Shi, Yang ; Liu, Huilin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-ae17677ae11fcedde858c1d750d3b1e051d02667fedfba57204ca06bc7a7b9e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies - therapeutic use</topic><topic>apoB</topic><topic>Apolipoprotein B</topic><topic>Apolipoproteins</topic><topic>Apolipoproteins B - antagonists & inhibitors</topic><topic>CHO Cells</topic><topic>Complications</topic><topic>Cricetulus</topic><topic>Diabetes</topic><topic>Diabetes Complications - pathology</topic><topic>Diabetes Complications - therapy</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - pathology</topic><topic>Diabetes Mellitus - therapy</topic><topic>Diabetes Mellitus, Experimental - pathology</topic><topic>Diabetes Mellitus, Experimental - therapy</topic><topic>Diabetic complication</topic><topic>Display devices</topic><topic>Epitopes</topic><topic>Fusion protein</topic><topic>GLP-1</topic><topic>Glucagon-Like Peptide 1 - therapeutic use</topic><topic>Hep G2 Cells</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hyperlipidemia</topic><topic>Low density lipoprotein</topic><topic>Low-intensity ultrasound</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Phage display</topic><topic>Phages</topic><topic>Proteins</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Ultrasonic imaging</topic><topic>Ultrasonic testing</topic><topic>Ultrasonic Therapy - methods</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Xing</creatorcontrib><creatorcontrib>Bai, Lianjie</creatorcontrib><creatorcontrib>Zhang, Yinghui</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Shi, Yang</creatorcontrib><creatorcontrib>Liu, Huilin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Xing</au><au>Bai, Lianjie</au><au>Zhang, Yinghui</au><au>Wang, Ying</au><au>Shi, Yang</au><au>Liu, Huilin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel GLP-1/anti-apolipoprotein B bifunctional fusion protein alleviates diabetes and diabetic complications in combination with low-intensity ultrasound</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>278</volume><spage>119549</spage><epage>119549</epage><pages>119549-119549</pages><artnum>119549</artnum><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>To engineer and screen a novel GLP-1/anti-apolipoprotein B (apoB) bifunctional fusion protein with therapeutic potential on alleviating diabetes and diabetic complication in combination with low-intensity ultrasound.
Anti-apoB antibodies were screened by phage display technology and further fused to mutated GLP-1 (7–37) via light or heavy fusion to generate bifunctional fusion protein (termed aBG). The optimal design of aBG fusion protein was further confirmed by in vitro epitope competition assay and cAMP accumulation assay. Subsequently, chronic study in DIO mice were subjected to assess the long-term efficacy of screened fusion protein.
The selected GLP-1/anti-apoB fusion protein, aBG-8, exerted either the highest binding affinities for GLP-1R and apoB, or the greatest LDL-C uptake capacity and GLP-1R activation activity. After 60-day treatment in DIO mice, aBG-8 was proved to exert the promising improvement on hyperglycemia, hyperlipidemia, and obesity in DIO mice. Furthermore, combined therapy of aBG-8 and low-intensity ultrasound could accelerate skin wound closure in diabetic mice.
A novel long-lasting bifunctional fusion molecule, aBG-8, was designed with the enormous potential on alleviating diabetes and diabetic complications in combination with low-intensity ultrasound.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>33933459</pmid><doi>10.1016/j.lfs.2021.119549</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0024-3205 |
| ispartof | Life sciences (1973), 2021-08, Vol.278, p.119549-119549, Article 119549 |
| issn | 0024-3205 1879-0631 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2521497642 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antibodies Antibodies - therapeutic use apoB Apolipoprotein B Apolipoproteins Apolipoproteins B - antagonists & inhibitors CHO Cells Complications Cricetulus Diabetes Diabetes Complications - pathology Diabetes Complications - therapy Diabetes mellitus Diabetes Mellitus - pathology Diabetes Mellitus - therapy Diabetes Mellitus, Experimental - pathology Diabetes Mellitus, Experimental - therapy Diabetic complication Display devices Epitopes Fusion protein GLP-1 Glucagon-Like Peptide 1 - therapeutic use Hep G2 Cells Humans Hyperglycemia Hyperlipidemia Low density lipoprotein Low-intensity ultrasound Male Mice Mice, Inbred C57BL Phage display Phages Proteins Recombinant Fusion Proteins - therapeutic use Ultrasonic imaging Ultrasonic testing Ultrasonic Therapy - methods Ultrasound |
| title | Novel GLP-1/anti-apolipoprotein B bifunctional fusion protein alleviates diabetes and diabetic complications in combination with low-intensity ultrasound |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T04%3A00%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20GLP-1/anti-apolipoprotein%20B%20bifunctional%20fusion%20protein%20alleviates%20diabetes%20and%20diabetic%20complications%20in%20combination%20with%20low-intensity%20ultrasound&rft.jtitle=Life%20sciences%20(1973)&rft.au=Li,%20Xing&rft.date=2021-08-01&rft.volume=278&rft.spage=119549&rft.epage=119549&rft.pages=119549-119549&rft.artnum=119549&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2021.119549&rft_dat=%3Cproquest_cross%3E2545254163%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2545254163&rft_id=info:pmid/33933459&rft_els_id=S002432052100535X&rfr_iscdi=true |